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We have demonstrated that SlyA activates fimB expression
and hence type 1 fimbriation, a virulence factor in Escherichia
coli. SlyA is shown to bind to two operator sites (OSA1 andOSA2),
situated between 194 and 167 base pairs upstream of the fimB
transcriptional start site. fimB expression is derepressed in an
hnsmutant anddiminishedby a slyAmutation in thepresenceof
H-NS only. H-NS binds tomultiple sites in the promoter region,
including two sites (H-NS2 and H-NS3) that overlap OSA1 and
OSA2, respectively. Mutations that disrupt either OSA1 or OSA2
eliminate or reduce the activating effect of SlyA but have differ-
ent effects on the level of expression. We interpret these results
as reflecting the relative competition between SlyA and H-NS
binding. Moreover we show that SlyA is capable of displacing
H-NS from its binding sites in vitro. We suggest SlyA binding
prevents H-NS binding to H-NS2 and H-NS3 and the subse-
quent oligomerization of H-NS necessary for full inhibition of
fimB expression. In addition, we show that SlyA activates fimB
expression independently of two other known regulators of
fimB expression, NanR and NagC. It is demonstrated that the
rarely usedUUGinitiation codon limits slyA expression and that
low SlyA levels limit fimB expression. Furthermore, Western
blot analysis shows that cells grown in rich-defined medium
contain 1000 SlyA dimers per cell whereas those grown in
minimal medium contain>20% more SlyA. This study extends
our understanding of the role that SlyA plays in the host-bacte-
rial relationship.
Bacterial-host attachment is a key step in colonization and
pathogenesis. Although the type 1 fimbrial adhesin of Esche-
richia coli is produced by the majority of non-pathogenic as
well as pathogenic strains of the bacterium, it has been impli-
cated as a virulence factor in urinary tract and other infections
(1–4). Type 1 fimbriate cells attach to uroplakin receptors in
the bladder to facilitate invasion and the subsequent formation
of intracellular communities thought to be required for
chronic-recurrent UTI (5, 6). The adhesin is able to deliver LPS
to TLR4 and even directly activate the TLR4-MyD88 pathway
(5–7). This interaction produces an innate immune response in
the host, including the release of pro-inflammatory cytokines
IL-6, IL-8, and TNF- (5, 6).
Like many cell surface virulence factors, type 1 fimbriation is
controlled by phase variation that produces a mixture of
expressing (fimbriate) and non-expressing (afimbriate) bacte-
ria. Phase variation of type 1 fimbriation in E. coli requires the
site-specific inversion of a short (300 bp) segment of DNA
(fimS) that contains a promoter for the fimbrial structural
operon (8–10). Inversion is catalyzed by tyrosine family recom-
binases FimB and FimE, which are encoded by genes situated
adjacent to the fimbrial structural genes (11, 12). Whereas
FimB promotes low frequency (102 per cell per generation)
phase switching in either direction, FimE can generate rates of
fimbriate to afimbriate switching as high as 0.8 per cell per
generation (13–15).
The expression of both fimB and fimE, as well as the inver-
sion itself, are controlled bymultiple signals including the avail-
ability of the branched chain amino acids and alanine, temper-
ature, sialic acid (Neu5Ac), andN-acetylglucosamine (GlcNAc)
(15–17) among others. In addition to the signals noted above,
fimB expression, and hence type 1 fimbriation, is also
enhanced by the alarmones guanosine tetra- and pentaphos-
phate ((p)ppGpp)2 (18). The response to many of the signals
described above should decrease the fimbriate cell population
during host inflammation, and we have proposed the raison
d’eˆtre for the regulation observed in E. coli K-12 is to help bal-
ance the host-parasite interaction (16, 17, 19). Inversion of fimS
can also be catalyzed by homologous recombinases encoded at
a distant location in some clinical isolates (20, 21), raising the
possibility that OFF-to-ON phase switching is less sensitive to
such signals in strains showing greater pathogenicity.
TheMarR-family member SlyA was originally identified as a
regulator of virulence in Salmonella, where it is required for
intracellular survival and systemic pathogenesis (22). SlyA is
also found in E. coliwhere it was first shown to activate expres-
sion of the cryptic hemolysin gene hlyE (also known as clyA or
sheA) (23). Proteomic analysis of the SlyA regulons of entero-
invasive E. coli (EIEC) and Salmonella revealed that SlyA posi-
tively or negatively controls the expression of over 30 proteins
in each bacterium (24). This study, together with more recent
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work (25), shows that there is little overlap in the SlyA regulons
of the two organisms. Perhaps surprisingly, all of the SlyA regu-
lon members identified in EIEC, including those involved in
heat and acid stress responses and a variety of metabolic func-
tions, are also found in E. coli K-12. However, SlyA has also
been shown to activate expression of the K5 capsule, which is a
virulence factor in UPEC (26, 27).
Notwithstanding these differences between the SlyA regu-
lons ofE. coli and Salmonellanoted above, in all caseswhere the
mechanism of SlyA control has been characterized in detail,
SlyA regulates gene expression by interacting with the abun-
dant nucleoid-associated protein H-NS (27–30). However
while SlyA antagonizes H-NS repression of the majority of
genes which it activates in both E. coli and Salmonella, remod-
eling of the H-NS nucleoprotein complex facilitates activation
of K5 capsule in E. coli (27). Here we show that SlyA antago-
nizes the inhibitory effect of H-NS on fimB expression. SlyA is
thus a novel activator of type 1 fimbriation in E. coli.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, Media, and Growth Conditions—
Descriptions and genotypes of bacterial strains are listed as sup-
plemental material [strains-pdf]. All the bacterial strains used
are derivatives of the E. coli K-12 strain MG1655 (31). All plas-
mids used for allelic exchange are derivatives of the chloram-
phenicol resistant, temperature-sensitive vector pMAK705
(32). All reagents were obtained from Sigma unless otherwise
indicated. Media used included L broth (5 g of sodium chloride
(Fisher Scientific), 5 g of yeast extract (Oxoid), and 10 g of tryp-
tone (Becton-Dickinson & Co.) per liter) and L agar (L broth
with 1.5% agar (Difco)). Sucrose agar used to select recombi-
nant bacteria following allelic exchange was L agar supple-
mentedwith 6% sucrose in the absence of sodium chloride (33).
The antibiotics chloramphenicol (25 g/ml), tetracycline (10
g/ml) and kanamycin (25 g/ml) were included in selective
media as required. Minimal MOPS medium was prepared as
described by Neidhardt et al. (34), supplemented with 10 mM
thiamine and 0.4% glycerol (Fisher Scientific). To prepare rich-
defined medium, minimal MOPS medium was further supple-
mented with bases, vitamin B supplement and amino acids as
originally reported (34). Liquid cultures were grown aerobically
at 37 °C, and culture densities were monitored spectrophoto-
metrically at 420 or 600 nm.
Analysis of fimB Expression and FimB Recombination—fimB
expression was measured using a FimB-LacZ fusion situated in
the chromosome at fim as described previously (16). Mutant
fim regulatory alleles used in this study, including scanning-
replacementmutations in which adjacent segments of the fimB
promoter were replaced by 14–15 bp of heterologous DNA,
were cloned into derivatives of the temperature-sensitive vec-
tor pMAK705 (32), and allelic exchange was then used to trans-
fer the mutations into the chromosome at fim using sacB and
sucrose counter-selection as described previously (33). P1
transduction was carried out using P1vir by standard proce-
dures (35).-Galactosidase assays were conducted as described
by Miller (36), following growth in either rich defined or mini-
mal medium at 37 °C with rapid aeration to an A600 of 0.2.
Experiments were repeated at least twice, and the values shown
represent themeanof at least four sampleswith 95%confidence
intervals included for each value.
FimB recombination was measured as described previously
(15). Bacteria were first plated onto lactose-MacConkey indica-
tor medium to isolate phase OFF colonies. A single colony was
subsequently inoculated into RD media, and grown at 37 °C to
an A420 of 0.1. The cells were then diluted into 25 tubes to a
density of0.3 cells per tube, and grown for22 generations at
37 °Cwith rapid aeration. The proportion of phaseON to phase
OFF cellswas determined by plating samples of the culture (5–7
duplicates) onto lactose-MacConkey indicator medium. The
values shown represent the average obtained, together with the
minimum and maximum.
Purification of SlyA—Cultures of E. coli strain BL21(DE3)
containing slyA-pGS21a (GST-His-tagged SlyA overexpression
plasmid constructed by GenScript) were grown in LB supple-
mented with 125g/ml ampicillin, shaking at 200 rpm at 37 °C.
To overexpress the GST-His-tagged SlyA fusion protein, iso-
propyl -D-thiogalactopyranoside was added to the cultures to
a final concentration of 1mMwhen the cultures reached anA600
of 0.6. Following a further 3 h of incubation, the cultures were
cooled on ice for 10 min, and the cells were then pelleted by
centrifugation at 8000 g for 10 min at 4 °C. Cell pellets were
frozen at20 °C and then resuspended in Lysis Buffer (50 mM
Tris-HCl, 2 mM EDTA, pH 8.0). Lysozyme (100 g/ml) and
TritonX-100 (0.1%) were added and themixture was incubated
for 20min at room temperature. For DNase I treatment,MgCl2
(10mM) and DNase I (20g/ml) were added, and samples were
incubated at room temperature for a further 30min, or until the
viscosity was reduced. Supernatant was collected by centrifu-
gation at 12,000  g for 10 min at 4 °C prior to loading onto a
glutathione-Sepharose 4B column (GE Healthcare) equili-
brated with Binding Buffer (140 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.3). The column was then
washed with 5 column volumes of Binding Buffer three times.
The GST-His-tagged SlyA was eluted by adding 0.5 ml of Elu-
tion Buffer (50 mM Tris-HCl, 0.25 M NaCl, 10 mM reduced glu-
tathione, pH 8.0) per ml bed volume of glutathione-Sepharose
4B. Fractions enriched for GST-His-tagged SlyA were pooled
and dialyzed against 50 mMTris-HCl, pH 8.0. The GST-His tag
was removed by cleavagewithHis-tagged recombinant tobacco
etch virus protease (Promega). The cleavage reaction was
applied to aNickel affinity column and tag-free SlyAwas eluted
with a 50mM imidazole solution (50mM imidazole, Tris-HCl 50
mM, 0.25 M NaCl, pH 8.0). Purified SlyA was finally dialyzed
against 50 mM Tris-HCl, pH 8.0.
Western Blot Analysis of SlyA—1.5 mg of purified SlyA pro-
tein was prepared for antibody generation at Eurogentec. After
immunization of 2 rabbits with 4 injections each during 28 days
(Speedy polyclonal packages), preimmune, medium, and final
bleeds were collected. The final bleed serum only was used for
Western blot analysis. For Western blot analysis, E. coli strains
were grown in rich defined or minimal media with rapid aera-
tion to reach anA600 of 0.2. Cells were cooled on ice for 10min,
pelleted by centrifugation at 8000  g for 10 min at 4 °C, and
then lysed and treated with DNase I as described above. After
centrifugation at 12,000 g for 10 min at 4 °C, the supernatant
of cell lysates was collected, and the concentration of total pro-
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tein was determined by the Bradford method. 68.5 ng of puri-
fied SlyA and 62 g of total protein from cell extracts were
subjected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) using 5% stacking and 17.5% separat-
ing gels. The proteins were transferred from the gel onto poly-
vinylidene difluoride membrane (PVDF, Millipore) for 1 h by
using a current of 0.15–0.20 A. The membrane was blocked by
incubation with 5%Dried SkimmedMilk in PBS/T (phosphate-
buffered saline 0.2% Tween 20) for 40 min at room temper-
ature, then incubated with primary antibody (1:1000 rabbit
serum) for 1 h at room temperature. After three washes with
PBS/T, the membrane was incubated with secondary antibody
(1:5000 goat anti-rabbit IgG-peroxidase, Sigma-Aldrich) for 30
min at room temperature, and again washed three times with
PBS/T. Proteins were visualized with enhanced chemilumines-
cence. Western blot films were scanned and processed using
ImageJ to quantify SlyA. The plot area of SlyA bands of each
strain weremeasured and comparedwith the purified SlyA plot
area. The number of SlyA dimers were estimated by comparing
the total weight of protein per E. coli cell (0.156 pg in rich-
definedmedium and 0.45 pg inminimalmedium as reported by
Bremer andDennis (37)) to the weight of a SlyA dimer (0.543
107 pg).
DNA Manipulations—Plasmid DNA was isolated with a kit
from Qiagen. Restriction and DNA modifying enzymes were
purchased from either Promega or New England Biolabs. PWO
DNA polymerase used in PCR reactions was obtained from
Roche. PCR and restriction endonuclease digestions were car-
ried out according to the manufacturers’ recommendations.
Deletion and replacement mutations were constructed using
standard PCR techniques (38) and/or restriction endonuclease
digestions, and used to replace wild type sequences cloned into
derivatives of the temperature-sensitive vector, pMAK705 (32).
Replacement mutations rm21–35, 14–17 bp in length, each
contained a SacII restriction endonuclease site (5-CCGCGG).
Replacement mutations rm39–41, 12 bp in length, were iden-
tical and contained a BsiWI restriction endonuclease site (5-
CGTACG). DNA sequencing was performed by Lark Technol-
ogies/Cogenics (nowBeckmanCoulter Genomics). Kanamycin
resistance cassettes of Keio collection origin (39) were cured as
described (40). All other molecular genetic procedures were
carried out according to standard protocols (38, 41).
EMSA and DNaseI Footprinting—Purified tag-free SlyA was
produced by GenScript, and H-NS was obtained as a generous
gift from Sylvie Rimsky. The fimDNA fragment used in EMSA
was generated using primers EMSAfim03f (5-CCCGGATCC-
GTAGTGACCAAAGC) and EMSAfim03r (5-CCCGTCGA-
CATAAAAAATTCAGC). A positive control for SlyA experi-
ments containing slyA promoter DNA was generated using
primers slyAf3 (5-CCCCGGATCCTGACGGTAACCAAAT-
GCAGCAATACATTTG) and EMSAsly01r (5-CCCGT-
CGACGATGGTCTATCAGAGCACG), spanning the region
reported to contain a SlyA binding site (27). A negative control
was amplified from pBluescript as previously reported (21).
Polyacrylamide gels were cast containing 5% acrylamide (Bio-
Rad) and 2% glycerol (Fisher Scientific). Reaction buffer con-
tained 10mMTris (Fisher Scientific) pH 9.0, 50mMKCl (Fisher
Scientific), and 0.1% Triton X-100, as used previously (42).
Reactionswere carried out in a final volume of 10l. EachDNA
fragment was incubated at a final concentration of 11 nM with
varying concentrations of SlyA or H-NS for 10 min, before
addition of 2 l of loading buffer (40% sucrose, 35 mM Tris, pH
8.0). Electrophoresis was immediately carried out in 1TBE at
160 V before staining for 15 min in 0.5 g/ml ethidium
bromide.
The fim03 fragment (Fig. 1) wasmade by PCRwith either the
fim03f or fim03r oligonucleotide labeled by [-32P]ATP and
polynucleotide kinase. DNase footprinting was carried out in
two different buffers: the H-NS buffer described by Bouffar-
tigues et al. (43) (2007) 40 mM Hepes, 60 mM potassium gluta-
mate, pH 8.0, 5 mMMgCl2, 0.05% Nonidet P40, 5 mM DTT, 0.5
mg/ml BSA, and the “SlyA” buffer described by Zhao et al. (44)
10 mM Tris, pH 7.5, 10 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 5
mmDTT, 5%glycerol, 0.5mg/mlBSA.Complexeswere formed
at 25 °C in a final volume of 40l and DNase attack was carried
out for generally 1 min with a final concentration of 50 ng/ml
DNaseI. H-NS protects DNA fromDNaseI and digestion times
were increased in the presence of 100 nM H-NS. Reactions
were stopped with 100 l of aqua phenol pH 8.0 and 200 l of
0.4 M sodium acetate (pH 5.0) 2.5 mM EDTA, 10 g/ml soni-
cated herring sperm DNA was added. The digested DNA was
phenol extracted, ethanol precipitated, and separated on 6%
denaturing acrylamide gels. The radioactive gels were analyzed
by phosphoimagery. The size marker is pBR322 DNA digested
withMspI (New England Biolabs) and labeled with [-32P]ATP
and polynucleotide kinase.
RESULTS
SlyA Activates fimB Expression—A set of adjacent scanning-
replacement mutations, extending from 38 to 184 bp
upstream of the fimB transcription start site, were constructed
and characterized in a chromosomal FimB-LacZ protein fusion
background. This was initially carried out as part of an analysis
of how the regulators NanR andNagC activate fimB expression
(45). Whereas none of these mutations affected the responses
toNanR orNagC (data not shown), the first two adjacentmuta-
tions (rm21 and rm22; Fig. 1) did diminish fimB expression (Fig.
2A). The nucleotide sequence mutated in rm21 and rm22 con-
tains a close match (5-TTAGCATGATAA; hereafter called
OSA1; boxed in Fig. 1B) to a consensus recognition sequence
for the transcriptional regulator SlyA (5-TTAGCAAG-
CTAA (42)), suggesting that SlyA might be an activator of
fimB expression.
To test this hypothesis, the slyA mutation of the Keio col-
lection (39) was transduced into the FimB-LacZ fusion. It was
found that expression of the fusion was diminished almost
4-fold in the mutant background following growth in rich-de-
finedMOPS glycerol medium (Fig. 2). Moreover, in contrast to
NanR and to NagC (data not shown), rm21 and rm22 had little
effect on fimB expression in the absence of SlyA (Fig. 2A). In a
control experiment it was also found that the effect of theslyA
mutation on fimB expression was complemented by an ectopic
copy of slyA placed in the chromosome at lac. This construct
(lacUV5-slyAUUG) included the slyA open reading frame,
together with 65 bp of upstream DNA, placed downstream of
the lacZYA promoter (Fig. 2B).
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SlyA Binds to the fimB Regulatory Region—To determine
whether SlyA binds to the putative operator OSA1, the interac-
tion of SlyA with the fimB promoter region was investigated by
EMSA and DNase I footprinting (Fig. 3). For this analysis, a
297-bp PCR product that includes 282 bp of fim sequences,
extending from 45 to 327 bp upstream of the fimB tran-
scriptional start site (Fig. 1) was used.
In EMSA, SlyA produced a loss of the free fimDNA, whereas
it had no effect on the pBluescript DNA negative control as
expected (27) (Fig. 3A). SlyA also bound to its own promoter as
expected from previous work (27, 42) (data not shown). How-
ever, SlyA produced only a faint discrete mobility-shifted band
with either the fim (arrow in Fig. 3A) or slyA substrates. In
repeat experiments, between 16 and 27 nM SlyA dimer was
required to diminish the amount of the free fim DNA by 50%
(not shown).
DNase I footprinting demonstrated that SlyA bound to a
region of DNA 40 bp long, spanning OSA1 and extending
around 20 bp further upstream relative to the fimB transcrip-
tional start site (Fig. 3B). A DNaseI hypersensitive site near
position 161 appears to delimit the downstream protected
region. Thus SlyA binds to OSA1 as predicted. The nucleotide
sequence adjacent to OSA1contains a second potential SlyA
operator site (5-CTAGGGACCTAA; hereafter called OSA2),
situated 3 bp upstream ofOSA1. BothOSA1 andOSA2 are altered
by rm21 (Fig. 1). The whole 40 bp region is simultaneously
protected by different concentrations of SlyA suggesting it cor-
responds to a single site. Despite the fact that the SlyA consen-
sus is only 12 bp long,most SlyA-protected regions described in
the literature are at least 40 bp long and are often bounded by
hypersensitive DNaseI cleavages (27, 28). Aweaker level of pro-
tection was also observed in a region closer to the fimB pro-
moter. However, mutation of this region did not alter the
response of fimB expression to SlyA and the potential impor-
tance of this region was not investigated further (data not
shown).
Mutagenesis of Potential SlyA Operators—To examine the
possible roles of OSA1and OSA2 further, two additional muta-
tions which targeted OSA1 (rm39) and OSA2(rm40) specifically
were constructed and their effects on fimB expression were
characterized (Fig. 1 and 4A). Surprisingly, although the OSA2
mutation decreased fimB expression substantially in the slyA
background, the OSA1 mutation affected fimB expression to
only a small extent. However, in both of the rm slyA double
mutants, the rmmutations each largely suppressed the activat-
ing effect of SlyAon fimB expression, supporting the hypothesis
that both OSA1 and OSA2 are SlyA operators as proposed.
It is notable that although all the fourmutations rm21, 22, 39,
and 40 eliminated themajority of the slyAmediated stimulation
of fimB expression they had different effects on the basal fimB
expression in the slyA mutant. Expression in the rm22 and
FIGURE 1. Organization of the region upstream of the fimB open reading frame. A, location of operator sites for NagC (ONC2) and SlyA (OSA1 and OSA2),
together with the fimB promoter, are indicated. The regions bound by H-NS for which a match to a consensus H-NS binding site (51) was identified are also
shown (H-NS1 to H-NS3). The fim DNA included in the amplicon used for EMSA and DNase I footprinting experiments is likewise indicated (fim03). The NagC
binding siteONC2was reported previously (45). B, wild type nucleotide sequence encompassingOSA1 andOSA2 are boxed. The nucleotide sequences ofmatches
to H-NS binding site consensus are labeled (H-NS2 and H-NS3) and are emphasized in bold text. The mutated sequences designated rm21, rm22, rm35, rm39,
and rm40 are shown beneath.
FIGURE 2. The effects of replacementmutations and slyA on the-galac-
tosidaseproducedbyaFimB-LacZ fusion.A, effects ofmutations rm21 and
rm22 in the presence of a wild type (dark bars) and deleted (light bars) slyA
gene. Error bars indicate 95% confidence values calculated from four repli-
cate experiments. Strains BGEC905, KCEC1243, KCEC1077, KCEC1271,
KCEC1079, and KCEC1273, listed in supplemental material [strains-pdf], were
grown in rich-defined glycerol medium and processed as described under
“Experimental Procedures.” B, effect of 0.1 mM IPTG (light bars) versus 0 mM
IPTG (dark bars) in wild type, slyA and slyA lacUV5-slyA backgrounds.
Strains BGEC905, KCEC1334, KCEC1494, and KCEC1765 were used. Error bars
and experimental conditions as A.
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rm39 mutants, and to a lesser extent the rm21 mutant, actually
increased. One hypothesis to explain these results is that the
mutations rm21, rm22, and rm39 also affect the binding of a
repressor of fimB expression.
SlyA Activates fimB Expression by Antagonizing H-NS Re-
pression—It has been shown that SlyA antagonizes H-NS
repression of hlyE expression, apparently by steric hindrance
when the two proteins compete for overlapping operators
(28, 48). Moreover it is known that H-NS inhibits fimB
expression (49). As shown in Fig. 4B, the activating effect of
SlyA on fimB expression is suppressed in an hns mutant.
Indeed in the absence of H-NS, SlyA actually seems to inhibit
fimB expression. While these results demonstrate that SlyA
can exert opposing effects on fimB expression, it is apparent
that SlyA has a net activating effect on fimB expression in the
wild type background by somehow antagonizing H-NS
repression.
H-NS Binding to the fimBUpstream Region with and without
SlyA—Prior work showed that H-NS binds in the vicinity of the
fimB promoter, but the location of the binding sites was not
determined (49). In DNase I footprinting experiments, we have
found that H-NS bound to an extensive region of the fimB pro-
moter, producing specific protection at short (10–20 bp)
sequences in a region that extended from about 500 bp
upstream to about 150 bp downstream of the transcriptional
start site (data not shown) similar to that observed at other
H-NS sites (for examples, see (29, 43)).
As predicted from the results described above, H-NS bound
to regions overlapping theDNA sequence protected by SlyA. In
particular, H-NS protected two regions (called H-NS2 and
H-NS3) which overlapped the SlyA binding site, and more
weakly a third region (H-NS4) further upstream (Figs. 1 and 5A,
lanes 2–4). The H-NS2 and H-NS3 (5-ATGATAATAG and
GCGATTATTC, appearing on the top and bottom stands in
Fig. 1, respectively) each contain 5/10 bp matches to the H-NS
site (5-TCGATAAATT) proposed by Lang et al. (51). H-NS4
does not contain a discernable match.
Adding SlyA (2 M) had no effect on H-NS binding and only
when H-NS binding was lost (at 25 and 50 nM H-NS) was SlyA
binding to its site detected (Fig. 5A, lanes 5, 6, 11, and 12). These
experiments were performed in a Hepes-glutamate buffer pre-
viously described for use with H-NS (43). We noted however
FIGURE 3. The interaction of SlyA with the fimB promoter region in
vitro. A, effect of 0, 15, 30, 60, and 120 nM SlyA dimer on the electophoretic
mobility of DNA amplicons fim03 and pBS (each 11 nM). Amplicon fim03 is
282 bp of the region upstream of fimB and includes OSA1 and OSA2 (Fig. 1).
Amplicon pBS is a negative control as previously described (27). The SlyA-
DNA complex is indicated with an arrow. Samples were separated on a 5%
polyacrylamide gel. Electrophoresis was carried out at 160 V for 35 min as
described under “Experimental Procedures.” B, DNase I footprinting. The
fim03 fragment, labeled at the fim03r end, was mixed with decreasing
concentrations of SlyA for 15 min at 25 °C before digestion with DNaseI.
Lane 1, no SlyA; lane 2, 1 M SlyA; lane 3, 500 nM; lane 4, 250 nM; lane 5, 125
nM; lane 6, 62.5 nM; lane 7, 31 nM; lane 8, 15.6 nM. The products were ana-
lyzed on a 6% denaturing polyacrylamide gel. Regions protected by SlyA
are indicated. The marker is pBR322 digested with MspI, and the sizes of
the fragments were used to calculate their positions relative to the tran-
scriptional start site of fimB (1).
FIGURE 4. The effects of replacement mutations and hns deletion on the
-galactosidase produced by a FimB-LacZ fusion in the presence and
absence of SlyA. A, effects of mutations rm35, rm39, and rm40 in the wild
type (dark bars) and slyA mutant (light bars). Strains BGEC905, KCEC1243,
KCEC1831, KCEC1854, KCEC2014, KCEC2016, KCEC2020, and KCEC2022 were
used. B, effect of an hns::mTn10 mutation in the presence of the wild type
(dark bars) or deleted (light bars) slyA gene. Strains BGEC905, KCEC1243,
KCEC755, and KCEC1300 were used. Error bars and experimental conditions
are described in Fig. 2.
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that many workers have preferred to study SlyA binding using
lower salt buffers (42, 44). Using the buffer used by Zhao et al.
(44), SlyA bound to the same sites although with higher affinity
(Fig. 5B, lanes 2 and 3). In this buffer H-NS also bound to the
H-NS2 and H-NS3 sites, but protection was extended in the
direction of fimB (site H-NS1) and reduced at H-NS4 (Fig. 5B,
lanes 4 and 5). H-NS1 actually contains a 7/10 match to the
H-NS consensus. In addition, there were several hypersensitive
DNaseI cleavages (indicated by arrows), which were not
observed in the “H-NS” buffer, suggesting that the structure of
the H-NS-DNA complex is dependent upon the ionic condi-
tions. This observation is in agreement with a recent publica-
tion which demonstrated that H-NS binds to DNA in two dif-
ferent modes, a “stiffening” mode and a “bridging” mode,
depending upon salt and divalent cation composition (50). The
low salt, low Mg2 “SlyA” buffer is compatible with the “stiff-
ening”mode of H-NS binding, whichwas proposed to be impli-
cated in the gene silencing function of H-NS. Thus, it is inter-
esting to note that in the “SlyA” buffer, SlyA was capable of
displacingH-NS from its binding sites, although it did require a
10-fold molar excess of SlyA (lanes 6 and 7). It should also be
noted that these experiments were performed on linear DNA
and the native supercoiled chromosome could influence the
binding characteristics.
Mutation rm21, which might be expected to disrupt both
OSA1 and H-NS2, seems mainly to eliminate SlyA activation.
This suggests that H-NS binding to H-NS3 alone might be suf-
ficient for repression of fimB expression. However the more
substantial increase in fimB expression seen in theslyA deriv-
atives of the otherOSA1mutants rm22 and rm39 (Figs. 2A and 4)
relative to the single slyAmutant suggests that this is not the
case.We have not been able to detect a decrease inH-NS binding
to the fimB promoter PCR fragment in these mutants by EMSA
(data not shown), though, suggesting that small local changes in
H-NS binding can affect the overall repression of fimB expression
by H-NS. The consensus match within H-NS3 overlaps with the
SlyAoperatorOSA2by1bp.Wenote that the rm40mutationof the
SlyA operatorOSA2 coincidently improves the homology between
the H-NS consensus and the match contained within H-NS3 by
altering the first base of this sequence from G to T (the C to A
transversion on the top strand shown in Fig. 1). Thus the unex-
pectedly large decrease in fimB expression seen in the rm40
mutant might reflect both diminished SlyA binding toOSA2 cou-
pled to increased binding of H-NS to H-NS3.
FIGURE 5. Competition between H-NS and SlyA binding upstream of the fimB promoter. A, binding of H-NS to the fim03 fragment labeled at the fim03f
end. Decreasing concentrations of H-NS were mixed with the fim03 DNAwith and without SlyA in the “HNS” buffer. Lane 1, no proteins; lanes 2 and 7, 400 nM
H-NS; lanes 3 and 8, 200 nMH-NS; lanes 4 and 9, 100 nMH-NS; lanes 5 and 10, 50 nMH-NS; lanes 6 and 12, 25 nMH-NS; lanes 7–12 also contained 2MSlyA. B, H-NS
bindingwith andwithout SlyA in the “SlyA” buffer. Lane 1, no proteins; lane 2, 50 nM SlyA; lane 3, 1M SlyA; lane 4, 50 nMH-NS; lane 5, 100 nMH-NS; lane 6, 1M
SlyA, and 50 nM H-NS; lane 7, 1 M SlyA and 100 nM H-NS. Proteins were incubated for 15 min at 25 °C before treatment with DNase I. Products were analyzed
on 6%denaturing polyacrylamide gels. Regions protected byH-NS and SlyA are indicated. The arrows indicate hypersensitive DNaseI cleavages on theDNA in
the presence of H-NS, which are observed in the “SlyA” buffer (B) but not in the “H-NS” buffer (H-NS). The marker is pBR322 digested with MspI, and the sizes
of the fragments were used to calculate their positions relative to the transcriptional start site of fimB (1).
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We have constructed an additional scanning-replacement
mutation that extends fromOSA2 further upstream of fimB that
partially replaces OSA2 while replacing the H-NS3 sequence
entirely (rm35, Fig. 1). Analysis of the effects of thismutation on
fimB expression shows that while it has very little effect in the
wild type (slyA) background, it produces a 3-fold increase in
the slyA mutant background, implying that H-NS binding has
been significantly diminished (Fig. 4A). This result supports the
hypothesis that H-NS binding to H-NS3 inhibits fimB expres-
sion and that SlyAbinding to the overlapping operator siteOSA2
counteracts this.
SlyA Limits fimB Expression and Produces Differential Con-
trol of fimB Expression in Rich and Minimal Medium—The
slyA open reading frame starts with an unusual UUG codon
(46), suggesting that a poor level of translation initiation of slyA
limits the protein expression. In agreement with this hypothe-
sis, it was found that replacing the native UUG initiation codon
with an AUG codon enhanced the level of SlyA that was
detected by Western blot analysis over 5-fold (Fig. 6). The
lacUV5-slyAAUG construct also increased SlyA levels to well
above that produced by the wild type and enhanced fimB
expression to above wild type levels too (Figs. 6 and 2B, respec-
tively). Thus poor translation initiation of slyA limits slyA
expression and hence fimB expression.
The level of expression of poorly-translated proteins gener-
ally rise as growth rate declines because of diminished compe-
tition with highly translated ribosomal and other proteins for
limiting translation factors (47). This suggested that SlyA
should have a larger effect on fimB expression in minimal
medium than it would in rich medium. In agreement with this
prediction, SlyA levels were higher in minimal medium than in
rich medium (Fig. 6) and the effect of SlyA on fimB expression
was enhanced too (Fig. 7). We estimated that there are 1036
dimers (the mean of duplicate estimates of 1012 and 1060) of
SlyA in exponential-phase cells grown in rich defined medium
and 21% more SlyA in cells grown in minimal medium (the
mean of 1280 and 1230). It should be noted that in estimating
the levels of SlyA in the different media, we have taken into
account the3-fold higher total protein content of cells grown
in rich medium than in minimal medium (37).
The Effect of SlyA on the Response of fimB Expression to NanR
and NagC—The mutations rm21 and rm22 have no effect on
the ability of either NanR or NagC to activate fimB expression
(data not shown), suggesting that SlyA controls fimB expres-
sion independently of either NanR or NagC. As anticipated,
combination of the slyA andnanRornagCmutations decreased
fimB expression levels further than did the single mutations
alone, as did inclusion of either Neu5Ac (the inducer of NanR)
or GlcNAc (the inducer of NagC) in the growth medium of the
slyAmutant (Fig. 8). Thus fimB expression is activated by mul-
tiple factors, with SlyA having a greater effect than either NanR
or NagC have.
The Effect of SlyA on Type 1 Fimbriation—Low levels of fimB
expression limit FimB-mediated recombination, and hence
OFF-to-ON phase switching, under the conditions used in this
study (16). As anticipated, the rate of FimB recombination was
over 12-fold lower in the slyA mutant (Table 1). Furthermore,
as judged by a decreased level of yeast cell agglutination, dele-
tion of slyA in the wild type Fim background (strainMG1655)
also diminished type 1 fimbriation as expected (Fig. 9).
FIGURE 6.Western blot analysis of slyA expression. 68.5 ng of purified SlyA
(P; lane 1), or 62 g of total protein isolated from the strains indicated (lanes
2–8), were subject to SDS-PAGE andWestern blot analysis as describedunder
“Experimental Procedures.” Extracts were made from the wild type strain
(BGEC905) grown in rich-defined glycerol medium (wt R; lane 2) or minimal
glycerolmedium (wtM; lane 3). All the additional strains analyzed (lanes 4–8)
were grown in rich-definedglycerolmedium.All extractswere prepared from
cultures grown to an A600	 0.2. Lane 4 (slyA)slyAmutant (KCEC1334); lanes
5 and 6, the lacUV5-slyAUUG construct (KCEC1494); lanes 7 and 8, the lacUV5-
slyAAUG construct (KCEC1765). The lac fusion constructs were grown in the
absence (I) or presence (I) of 1 mM IPTG as indicated.
FIGURE 7. The effects of media on the -galactosidase produced by a
FimB-LacZ fusion in the presence and absence of SlyA. Strains BGEC905
(wild type;darkbars) andKCEC1334 (slyAmutant, light bars)wereused. Error
bars and experimental conditions are described in Fig. 2.
FIGURE 8. The effects of NanR and NagC and their respective inducers
Neu5Ac and GlcNAc on the -galactosidase produced by a FimB-LacZ
fusion in the presence and absence of SlyA. Strains BGEC905 (wild type),
KCEC357 (nanR), and KCEC505 (nagC) (dark bars) and slyAmutant deriv-
atives (light bars) of these strains KCEC1334, KCEC1275, and KCEC1278,
respectively,wereused. Errorbars andexperimental conditions aredescribed
in Fig. 2. 3 mM Neu5Ac or GlcNAc were included in the medium as indicated.
TABLE 1
Theeffectof a slyAmutationonFimB inversion in rich-definedglycerol
medium at 37° C from OFF-to-ON per cell per generation
Cells were grown for approximately 22 generations as described by Gally et al. (15).
The mean, together with minimum and maximum values obtained for replicate




Wild type 7.23 (1.1–29.2; AAEC370A)
slyA 0.58 (0.0–1.1; KCEC1360)
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In contrast, SlyA had almost no effect on the expression of a
FimE-LacZ fusion (data not shown). Moreover, the level of
yeast agglutination of a strain containing the fim switch locked
in theONor fimbriate orientationwas unaffected by SlyA (data
not shown). Thus the effect of SlyA on fimB expression
described in detail above seems to be sufficient to explain how
SlyA affects both FimB recombination and type 1 fimbriation.
DISCUSSION
The phase-variable expression of type 1 fimbriation in E. coli
is regulated by a range of environmental signals. Some of these,
such as the availability of the branched-chain amino acids and
alanine, directly affect the DNA inversion controlling phase
variation mediated by both FimB and FimE to alter phase
switching from both the afimbriate to fimbriate phase and vice
versa. Others, however, including exogenous sialic acid and
N-acetylglucosamine, exert a specific effect on the direction of
phase variation by controlling fimB expression selectively. Here
we identify SlyA as a novel and specific activator of fimB expres-
sion and hence type 1 fimbriation.
In initial experiments it was found that mutagenesis of the
DNA sequence extending from 184 to 155 bp upstream of
the fimB transcriptional start site diminished fimB expression.
Inspection of the wild type sequence in this region showed that
it contains a close match (5-TTAGCATGATAA; extending
from179 to168 bp) to the consensus binding site for SlyA
(5-TTAGCAAGCTAA) proposed by Stapleton et al. (42). The
fim sequence, which we have calledOSA1, differs from the con-
sensus at only two positions (1A changed to T and 3C changed
to A, according to the numbering adopted by Haider et al.
(5 6T5T4A3G2C1A1A2G3C4T5A6A)) (52). Further-
more the sequences 5 6T5T4A and 5 4T5A6A, shown by
Haider et al. (52) to be most important for SlyA binding, are
conserved in OSA1. In DNase I footprinting experiments it was
shown that SlyA binds to OSA1 thus protecting the DNA from
digestion. Deletion of slyA diminished fimB expression and this
defect was complemented by an ectopic copy of slyA placed
under control of the lacUV5 promoter at lac. Moreover muta-
tions that disrupt OSA1 (rm21, 22, and 39) greatly diminish the
activating effect of SlyA on fimB expression. These results show
that SlyA is an activator of fimB expression and that OSA1 is
required for this effect. However the SlyA binding site charac-
terized by DNase I footprinting extends further upstream than
OSA1 and includes a second potential SlyA operator (5-
CTAGGGACCTAA; OSA2, extending from 194 to 183)
three bases pairs upstream of OSA1. OSA2 differs from the SlyA
consensus at four positions (6T changed to C, 2C changed to
G, 1A changed to G and 2G changed to C). Mutations that
disruptOSA2 (rm35 and rm40) also significantly reduce the acti-
vating effect of SlyA on fimB expression. Thus SlyA requires the
region covering both OSA1 and OSA2 to be able to activate fimB
expression fully.
H-NS is an inhibitor of fimB expression and was shown pre-
viously by EMSA to bind to the fimBpromoter region (49).Here
we have shown that the activating effect of SlyAon fimB expres-
sion is suppressed in the absence of H-NS. In common with a
number of other systems which SlyA controls (29, 48, 53), it
thus seems that SlyA activates fimB expression by somehow
preventing H-NS repression. We have found that H-NS pro-
tects a series of short (10–20 bp) sequences within a region
extending from at least 500 bp to around 150 bp down-
streamof the fimBpromoter fromattack byDNase I, suggesting
that SlyA could activate fimB expression by preventing H-NS
binding to the fimB promoter. At least two models have been
proposed for how SlyA antagonizes H-NS binding in other sys-
tems: “displacement,” implying direct competition between the
two proteins for overlapping binding sites, and “remodeling,”
where the binding of SlyA alters, but does not prevent, H-NS
binding (28, 29, 30). Two of theH-NS binding sites that we have
identified (H-NS2 and H-NS3) overlap the SlyA operator sites
OSA1 andOSA2, respectively, and at higher concentrations, SlyA
does prevent H-NS binding to both H-NS2 and H-NS3 under
one of the conditions tested. On the other hand, we see no
evidence in footprinting experiments that the two proteins can
bind simultaneously to the overlapping operator sites. However
we do note that SlyA might affect H-NS binding outside the
immediate SlyA protected regions; for example the hypersensi-
tive cleavages in the downstream part of the H-NS footprint of
Fig. 5B (near positions 110 and 80 lanes 4 and 5) are also
attenuated in the presence of SlyA (Fig. 5B, lanes 6 and 7).
Mutations ofOSA1 (rm21, 22, and 39) that would be expected
to diminish both SlyA and H-NS binding to their overlapping
sites have only a modest effect on fimB expression in the other-
wise wild type background. We note that a similar effect was
reported for mutations simultaneously affecting overlapping
SlyA and H-NS binding sites in the phoPQ promoter of Salmo-
nella typhimurium (54). Conversely, amutation ofOSA2 (rm40)
that would, if anything, be expected to enhance H-NS binding
toH-NS3by increasing thematch to consensus, decreased fimB
expression to a very low level.Wepropose thatH-NSbinding to
H-NS2 andH-NS3 serve as nucleation sites for oligomerization
of H-NS along the DNA that is necessary for full inhibition of
fimB expression (51, 55, 56).We suggest that the simplest inter-
FIGURE 9. Yeast agglutination experiment showing clumping indicative of type 1 fimbriation. Strains were grown to A600 2.0 in rich-defined glycerol
medium and mixed with a suspension of S. cerevisiae in a 1:1 ratio. Samples were incubated at room temperature for 30 s and then photographed. Strains
shown are AAEC554 (constitutively expressing type 1 fimbriae; lockedON), MG1655 (wild type), KCEC1235 (slyA::KanR), and AAEC072A (afimbriate;fimA-H).
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pretation of our data is that SlyA activates fimB expression by
binding toOSA1 andOSA2 to prevent, presumably by steric hin-
drance, H-NS binding to the overlapping operator sites H-NS2
and H-NS3, respectively.
We have shown previously that fimB expression is activated
by the regulators NanR (sialic acid-responsive) and NagC
(N-acetylglucosamine 6P-responsive) that bind to operators
(ONR and ONC1  ONC2 respectively) located between around
760 and 470 bp upstreamof the fimB promoter (16, 17, 45). One
possibility that we have considered is that SlyA affects the abil-
ity of these proteins to activate fimB expression. However,
mutants lacking SlyA remain fully responsive to NanR and to
NagC and their respective inducers Neu5Ac andGlcNAc. Thus
fimB expression is under complex and independent regulation
by multiple factors.
We have been unable to show an effect of ppGpp on the
binding activity of SlyA for fimB, as has been reported for SlyA
binding to the divergent pagD-pagC promoters of Salmonella
(44). These results emphasize the complexity of the regulation
of fimB expression and of FimB recombination and the need for
further analysis of both.
We estimate there are 1000 SlyA dimers present in expo-
nential-phase cells grown in rich defined glycerol medium.
SlyA, along with Lrp, somehow enhances the inhibitory effect
that type 1 fimbriation exerts overmotility (57).While the basis
for this effect requires further investigation, these and our
results show that SlyA not only activates type 1 fimbriation, but
that it also helps to coordinate adherence with other cellular
functions.Overall SlyA controls a regulon of at least 40 proteins
in EIEC (24) and our observation that SlyA is moderately abun-
dant is consistent with this observation. Among these, SlyA
represses the expression of ivy (ykfE), which encodes an inhib-
itor of C-lysozyme. The intact outer membrane is an effective
barrier against lysozyme, and we suppose that slyA expression
might be suppressed, and hence ivy induced, if the bacterial
outermembrane is damaged or even if its integrity is threatened
by host defenses or other stresses. Both type 1 fimbriae and the
K5 capsule are attached to the outermembrane, andwe suggest
that SlyA may contribute to a novel signaling pathway linking
cell structural robustness to the expression of these cell surface
virulence factors.
Our results also show that slyA expression is limited by its
poorly translated UUG initiation codon. These observations
are consistent with the conclusion that SlyA both limits fimB
expression and that it has a greater effect on fimB expression in
minimal medium than it does in rich-defined medium. How-
ever, these results also suggest that oxidative and nitrosative
stress, which limit methionine biosynthesis (58, 59), could lead
to even lower levels of slyA translation and hence fimB expres-
sion. Because SlyA controls fimB expression independently of
either NanR or NagC, such an effect could restrict fimB expres-
sion very substantially when combined with enhanced levels of
sialic acid in the course of host inflammation (16, 19, 45). We
thus propose that the regulation of fimB expression by SlyA
provides an additional mechanism that helps to limit type 1
fimbriation, and hence host adherence and invasion, when host
defensive mechanisms are activated.
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